

AP/CM



Robert Greene Sterne  
Edward J. Kessler  
John C. Kline  
David K.S. Cornwell  
Robert W. Esmond  
Tracy Gens G. Durkin  
Michael G. Hollabaugh  
Michael B. Ray  
Robert E. Sokohl  
Eric K. Steele  
Mark L. Steele  
Steven R. Ludwig  
John M. Cowen  
Lorraine M. Frazee  
Robert C. Milligan  
Donald J. Featherstone  
Timothy J. Shea, Jr  
Michael V. Messinger  
Judith U. Kim

Patrick E. Garrett  
George T. Helvey  
Hank J. Hirsch  
Elmira L. Ellison  
Thomas C. Flala  
Albert L. Fenzl  
Donald J. Giovannitti  
Peter A. Jackson  
Teresa U. Medler  
Jeffrey S. Weaver  
Kendra M. Weller  
Vincent L. Capuano  
Brian J. Del Buono  
Vivian Lee Dickey  
Theodore A. Wood  
Elizabeth J. Haanes  
Joseph S. Ostroff  
Frank R. Cunningham  
Christine M. Dohler

Rae Lynn P. Guest  
George S. Bandmerser  
Diane M. Baskin  
Jason D. Eisenberg  
Michael D. Specht  
Andrea L. Kamage  
Tracey L. Malone  
Jon E. Wright  
LuAnne M. DeSantis  
Amy E. Sunserfield  
Alec W. Tamm  
Helene C. Carlson  
Cynthia M. Bouchez  
Timothy J. Doyle  
Gaby L. Lengenborth  
Lori A. Gordon  
Nicole D. Detar  
Ted J. Ebersole  
Laura A. Vogel

Michael J. Manucco  
Bryan S. Wade  
Adam J. Edwards  
Michael G. Pean  
Shannon A. Carroll<sup>\*</sup>  
Wesley W. Cole  
Matthew J. Keay<sup>\*</sup>  
Nicole R. Kramer<sup>\*</sup>

Michelle K. Holoubek  
Simon J. Elliott  
Adam J. Edwards  
Mila McMurtry  
Scott M. Woodhouse  
Christopher J. Walsh  
Ulliana Di Nola-Baron  
Peter A. Macaris  
Jeffrey Mills

Registered Patent Agents:

Karen M. Kowalczyk  
Nancy J. Letts  
Matthew J. Dowd  
Kathrina Yuhua Pei Quach  
Bryan R. Bellino  
Robert A. Schwartzman  
Teresa A. Colella  
Jeffrey S. Lundgren  
Victoria S. Rutledge

Of Counsel:  
Kenneth C. Bass III  
Evan R. Smith  
Marvin C. Guthrie

\* Admitted only in Virginia  
+ Admitted only in Virginia  
# Practice Limited to Federal Agencies

August 8, 2005

WRITER'S DIRECT NUMBER:

(202) 772-8861

INTERNET ADDRESS:

CROUCHEZ@SKGF.COM

**Art Unit 1642**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Re: U.S. Utility Patent Application  
Application No. 09/675,650; Filed: September 29, 2000  
For: **PCA3 Messenger RNA Species in Benign and Malignant Prostate Tissue**  
Inventors: Busse *et al.*  
Our Ref: 1619.0080001/JAG/CMB

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Statement of Substance of Interview; and
2. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Cynthia M. Bouchez  
Attorney for Applicants  
Registration No. 47,438

JAG/CMB:krh

428772\_1.DOC



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Busse *et al.*

Application No.: 09/675,650

Filed: September 29, 2000

For: **PCA3 Messenger RNA Species in  
Benign and Malignant Prostate  
Tissue**

Confirmation No.: 1706

Art Unit: 1642

Examiner: Yu, Misook

Atty. Docket: 1619.0080001/JAG/CMB

**Statement of Substance of Interview**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicants note that an Interview Summary has been issued in the present matter. Hence, in accordance with 37 C.F.R. § 1.133(b) and MPEP § 713.04, Applicants' undersigned representative provides the following statement of the substance of the interview held with the Examiner in the above-indicated application.


The Examiner was contacted by telephone on July 6, 2005. Applicants requested that the Examiner provide the status of the pending claims. The Examiner asked Applicants to provide support for the following clause in amended claim 4 - "wherein said isolated nucleic acid molecule is differentially expressed in a non-malignant prostate." Applicants directed the Examiner to page 5, lines 21-26 of the specification.

On the USPTO Interview Summary dated July 8, 2005, the Examiner did not indicate that agreement was not reached, so Applicants believe that the Examiner viewed Applicants' description favorably.

Applicants respectfully request that this statement be entered into the record. It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19 0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

  
Cynthia M. Bouchez  
Attorney for Applicants  
Registration No. 47,438

Date: August 8, 2005

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600

428747\_1.DOC